Correlation of metabolic tumor burden with clinical outcomes in the ZUMA-7 trial. ICANS/CRS, incidence of grade 3⁺ immune effector cell–associated neurotoxicity syndrome/cytokine-release syndrome; MTV, metabolic tumor volume; PFS, progression-free survival; SOC, standard-of-care high-dose chemotherapy with autologous stem cell transplant. Figure created with BioRender.com.